Sandro Matosevic

Photo
Assistant Professor
Phone:
765-494-1400
Fax:
765-494-6545
Specialization: Immunotherapy, cell therapy, bio-nanotechnology, cryopreservation, controlled delivery, biopharmaceutical engineering

Education

The Scripps Research Institute - Postdoctoral Training, Chemistry
University College London - PhD, Biochemical Engineering
University College London and Rensselaer Polytechnic Institute - MEng with Study Abroad, Biochemical Engineering

Research

Dr. Matosevic’s research program focuses on developing new immunotherapies for solid tumors using translational tools to reprogram the therapeutic behavior of natural killer cells and their interaction with the tumor microenvironment by combining approaches in cell therapy, gene engineering, immunology and immunoengineering to (1) Overcome immunometabolic suppression of natural killer cell function in the tumor microenvironment via molecular modulation of their function; (2) Enhance natural killer cell anti-tumor immunity by engineering synthetic genetic constructs that can effectively target solid tumors; (3) Engineer novel cryopreservation platforms devoid of DMSO to improve patient safety upon administration of adoptive natural killer cell therapies. 

Lab Members

Andrea M. Chambers (Graduate Student with Dr. Sandro Matosevic)
Jenna Clingerman (PULSe Graduate Student)
Kyle B. Lupo (Graduate Student with Dr. Sandro Matosevic)
Jiao Wang (Post-Doctoral Research Associate with Dr. Sandro Matosevic)
Xue Yao (PULSe Graduate Student)

Representative Publications

Matosevic S. Viral and non-viral engineering of natural killer cells as emerging cancer immunotherapies. In press, 2018

Wang J, Matosevic S. Adenosinergic signaling as a target for natural killer cell immunotherapy. Journal of Molecular Medicine, 2018, doi.org/10.1007/s00109-018-1679-9

Lin-Gibson S, Hanrahan B, Matosevic S, Schnitzler A, Zhang J, Zylberberg C. Points to Consider for Cell Manufacturing Equipment and Components. Cell & Gene Therapy Insights, 2017, 3(10):793-805.

Pasley, Shannon, Zylberberg, Claudia; Matosevic, Sandro. Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in novel DMSO-free media. Immunology Letters (2017), 192:35-4.

Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapyGene Therapy, 2017, doi: 10.1038/gt.2017.41.

Zylberberg C and Matosevic S. Bioengineered liposome-scaffold composites as therapeutic delivery systems. Therapeutic Delivery, 2017, 8(6):425-445.

Zylberberg C and Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. 2016, Drug Delivery, 23(9):3319-3329.

Knapinska A, Amar S, He Z, Matosevic S, Zylberberg C, Fields G. Matrix metalloproteinases as reagents for cell isolation. Enzyme and Microbial Technology, 2016,

Matosevic S, Paegel BM. Layer-by-layer cell membrane assembly. Nature Chemistry, 2013, 5:958-963.

Matosevic S. State-of-the-art in the development of microfluidic technology toward the synthesis of artificial cells from giant unilamellar vesicles. BioEssays, 2012, 34(11):992-1001.

Matosevic S, Paegel BM. 2011. Stepwise synthesis of giant unilamellar lipid vesicles on a microfluidic assembly line. Journal of the American Chemical Society, 2011, 133(9):2798-2800.

Matosevic S, Lye GJ, Baganz F. Immobilised enzyme microreactor for the quantification of multi-step bioconversions: Characterisation of a de novo transketolase-omega-transaminase pathway to synthesise chiral amino alcohols. Journal of Biotechnology2011, 155(3):320-329

Matosevic S, Szita N, Baganz F. Fundamentals and applications of immobilized enzyme microreactors. J Chem Tech Biotech.86(3):325-334.

Matosevic S, Lye GJ, Baganz F. Development and characterization of a prototype immobilized enzyme microreactor: Quantification of transketolase kinetics. Biotechnology Progress, 2010, 26(1):118-126.

Matosevic S, Micheletti M, Lye GJ, Baganz F. Quantification of kinetics for en-zyme-catalysed reactions: implications for enzyme diffusional limitations at the 10 ml scale. Biotechnology Letters, 2008, 30(6):995-1000.

Venkiteshwaran A, Heider P, Matosevic S, Bogsnes A, Staby A, Sharfstein S, Belfort G. 2007. Optimized Removal of Soluble Host Cell Proteins for the Recovery of met-Human Growth Hormone Inclusion Bodies from Escherichia coli Cell Lysate Using Crossflow Microfiltration. Biotechnology Progress, 23(3):667-672.

Google Scholar profilehttps://scholar.google.com/citations?user=u0MWS_oAAAAJ&hl=en

Mega Menu Visual Content